SFOP-LMB and NHL-BFM are 2 classic treatment strategies for pediatric B-cell lymphoma and achieve an overall disease-free survival rate of 80% to 90%.[4,35] Several studies have shown that the addition of rituximab can help improve NHL outcomes at various risk levels.[36,37] However, given the myelotoxic effects, high cost, and drug resistance in the relapse stage,[38] this PRL child in the Stage III of the St. This evidence concerns the gene PRL and B-cell non-Hodgkin lymphoma.